Point of care testing for infectious diseases

Chen, Hui; Liu, Kengku; Zhao, Li; Wang, Ping

doi:10.1016/j.cca.2019.03.008

Cited by 207 publications

(148 citation statements)

References 143 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…In an environment where electricity availability is limited, easy-to-use and durable reagents and equipment are desirable. In recent years, attempts have been made to spread virus testing as point-of-care tests (POCT) [28]. For some pathogens such as malarial parasite (Plasmodium), HIV, Ebola virus, and Zika virus, development of the testing system by fluid device is in progress; however, HPV detection methods have not been put to practical use as POCT yet.…”

Section: Clinical Test For Hpv Detectionmentioning

confidence: 99%

Basic Research and Clinical Examination of Tumor Virus

Tsuruyama¹,

Ogawa²,

Yamada³

2020

Viruses and Viral Infections in Developing Countries

View full text Add to dashboard Cite

Tumor viruses cause cancer; thus, extensive studies are being conducted on them. In this article, we will review the basic medical research on the current clinical genetic tests for tumor viruses such as human papilloma virus, hepatitis B virus, and T-cell leukemia virus. Recently, clinical genetic tests have been developed for quick diagnosis of the tumor virus infection. Additionally, we will review the mutagenesis of murine leukemia retrovirus. In particular, we will focus on the insertional mutagenesis. This will help in deciding the direction of future virus research by combining clinical and basic research.

show abstract

Section: Clinical Test For Hpv Detectionmentioning

confidence: 99%

Basic Research and Clinical Examination of Tumor Virus

Tsuruyama¹,

Ogawa²,

Yamada³

2020

Viruses and Viral Infections in Developing Countries

View full text Add to dashboard Cite

show abstract

“…This opened the door to a range of medical applications, including transformative technologies for point of care monitoring and diagnostics devices. It's thus a timely occasion to review the successes of nanoparticles and sensors tailored to serve highly specific functions, from medical applications [2][3][4][5][6] to sensing the environment [7][8][9][10][11][12], as well as to ask where and when caution is warranted [13][14][15][16][17][18][19][20][21][22][23].…”

Section: Assessing the Progress Madementioning

confidence: 99%

Nanosensors and particles: a technology frontier with pitfalls

Vogel

2019

J Nanobiotechnol

View full text Add to dashboard Cite

As we are approaching 20 years after the US National Nanotechnology Initiative has been announced, whereby most of that funding was spend to engineer, characterize and bring nanoparticles and nanosensors to the market, it is timely to assess the progress made. Beyond revolutionizing nonmedical applications, including construction materials and the food industry, as well as in vitro medical diagnostics, the progress in bringing them into the clinic has been far slower than expected. Even though most of the advances in nanosensor and nanoparticle research and development have been paid for by disease-oriented funding agencies, much of the gained knowledge can now be applied to treat or learn more about our environment, including water, soil, microbes and plants. As the amount of engineered nanoparticles that enter our environment is currently exponentially increasing, much tighter attention needs to be paid to assessing their health risk. This is urgent as the asbestos story told us important lessons how financial interests arising from a rapid build up of a flourishing industry has blocked and is still preventing a worldwide ban on asbestos, nearly 100 years after the first health risks were reported.

show abstract

“…Portable, point-of-care (POC) technologies allow scientists, biologists, medical professionals and the public to take advanced diagnostics to the field [12]. Though not a new concept, few POC tools exist for domestic companion animal or livestock diagnostics.…”

Section: Introductionmentioning

confidence: 99%

“…Fewer have been developed and validated for use in wildlife and field settings [13]. However, recent outbreaks of Ebola in great apes and humans, SARS in civets, peste-des-petits ruminants in saiga, African swine fever, MERS in camels and humans, and many other diseases of animal and public health importance have highlighted a need for development of new or enhancement of existing portable POC tools [12,[14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a portable, point-of-care canine distemper virus qPCR test

et al. 2020

View full text Add to dashboard Cite

Canine distemper virus (CDV) is a multi-host pathogen that can cause significant mortality in domestic, wild terrestrial and marine mammals. It is a major conservation threat in some endangered species. Infection can result in severe respiratory disease and fatal encephalitis. Diagnosis and disease monitoring in wildlife, and differentiation of CDV from rabies (a lifethreatening zoonotic disease that can produce similar neurologic signs), would benefit from the availability of a portable, point-of-care (POC) diagnostic test. We therefore developed a quantitative RT-PCR assay for CDV using shelf-stable, lyophilized reagents and target-specific primers and probes for use with the handheld Biomeme two3™ qPCR thermocycler. Biomeme's extraction methodology, lyophilized reagents, and thermocycler were compared to our standard laboratory-based methods to assess sensitivity, efficiency and overall test performance. Results using a positive control plasmid for CDV showed comparable sensitivity (detection of 50 copies) and PCR efficiency between the two platforms, and CDV detection was similar between platforms when tested using a modified live CDV vaccine. Significantly higher Ct values (average Ct = 5.1 cycles) were observed using the Biomeme platform on known CDV positive animal samples. CDV detection using the Biomeme platform was similar in 25 of 26 samples from suspect CDV cases when compared to standard virology laboratory testing. One false positive was observed that was negative upon retest. The Biomeme methodology can be adapted for detection of specific targets, and this portable technology saves time by eliminating the need for local or international sample transport for laboratory-based diagnostics. However, results of our testing suggest that decreased diagnostic sensitivity (higher Ct values) relative to laboratory-based methods was observed using animal samples, so careful validation and optimization are essential. Portable qPCR platforms can empower biologists and wildlife health professionals in remote and low-resource settings, which will greatly improve our understanding of CDV disease ecology and associated conservation threats in wildlife.

show abstract

Point of care testing for infectious diseases

Cited by 207 publications

References 143 publications

Basic Research and Clinical Examination of Tumor Virus

Basic Research and Clinical Examination of Tumor Virus

Nanosensors and particles: a technology frontier with pitfalls

Development and validation of a portable, point-of-care canine distemper virus qPCR test

Contact Info

Product

Resources

About